Schedule-at-a-Glance is preliminary and will be updated as information becomes available. 

Frost & Sullivan's Medical Devices 2008.pdf

 

If you have any questions or concerns please feel free to contact us: 

	877-463-7678
	events.us@frost.com

SCHEDULE-AT-A-GLANCE

13th Annual Medical Devices Executive MindXchange Calendar of Events

General Session

Sunday, March 9, 2008: Networking Day Monday - Tuesday, March 10-11, 2008: Keynotes, Executive Bulletins, Success Stories, Growth Insights, Interactive Sessions, Networking Reception, and Exhibition Wednesday, March 12, 2008:  2nd Annual Venture Connections Executive Symposium Co-located with our annual Medical Devices 2008 Executive MindXchange, Venture Connections 2008 is a uniquely interactive forum delivering opportunities for a critical mass of companies seeking funding to showcase their business case to the venture capital community. Presenting companies have successfully advanced through the Frost & Sullivan Investment Scorecard -- a comprehensive examination of key investment criteria – and represent the most promising investment opportunities in the market today. For further information, visit (www.frost.com/vc).

Sunday, March 9th, 2008 - NETWORKING DAY
Bring plenty of business cards, relax, meet and greet during this fun-filled day devoted to making new contacts and new friends!
9:00am	Registration: Tour, Toast and Taste of Sonoma Valley
9:30am	Shuttle departure for Sonoma
6:30pm	Networking Reception
7:30pm	Networking Dinner

MONDAY, MARCH 10th, 2008 - GENERAL SESSION AND EXHIBITION
7:30am	Registration, Continental Breakfast and Exhibition
8:15am	Ice Breaker, Welcome and Introduction  Patrick Nugent, Executive MindXchange Chairperson, Frost & Sullivan
8:30am	EXECUTIVE BULLETIN    Your Passport to the Future of Medical Technologies  Greg Caressi, Vice President, Global Healthcare, Frost & Sullivan  To kick off the 2008 Executive MindXchange, Frost & Sullivan will provide  strategic insight into key trends and issues that are impacting the  healthcare industry. This session will cover macro issues impacting  healthcare providers, suppliers, technology development, payer and end  user communities. The speaker will discuss major trends and provide  details and analysis to support the strategic direction industry participants  are taking to address these issues.  The goal of this presentation is to  open discussions and frame key focus points that will be addressed in  other sessions during the course of the event.
9:00am	KEYNOTE  Perspectives on Healthcare Reform: Election Year 2008  Martha M. Kendrick, Partner, Patton Boggs, L.P.  This presentation discusses a macro level view of aging, health, wealth  and health insurance. The U.S. healthcare system is going through one of  the most turbulent periods of its history driven by reform and growing in  complexity and size as it attempts to meet the expanding needs of an  aging population. This keynote will provide an environmental assessment  of the U.S. healthcare market, the key trends and strategic forces shaping  its future, and the opportunities and challenges that will emerge.   Key Take-Aways: Health care policy shifts Reform Models Making Technology Pay  Price pressures Optimizing the value of healthcare expenditures
9:45am	EXECUTIVE INSIGHTS    The Burden of Evidence: Pay for Performance  Molly J. Coye, M.D., M.P.H., Chief Executive Officer, Health  Technology Center    In this presentation, the founder of HealthTech, a non-profit research and  education organization will provide insight into the Pay for Performance  movement including future trends for this initiative and what their affect  may be on the medical devices industry, how far the initiative may reach  and possible implications on the healthcare industry as a whole.  As a  member of the Institute of Medicine, Dr. Coye co-authored key reports  that are considered by many to be the backbone of the Pay for  Performance initiative including, To Err is Human and Crossing the Quality  Chasm, she also chaired the Committee on Access to Insurance for  Children, and co-chaired the Committee on Patient Safety Data Standards.   Key Take-Aways: A framework for Pay for Performance Understand future trends of Pay for Performance initiative Key implications for Medical Devices
10:30am	Networking, Refreshment and Exhibition Break
11:00am	INTERACTIVE Breakout Sessions: Create, Communicate & Connect  Participant-driven discussions focusing on your key challenges    and concerns.  Choose one of the following:  BP1: Maximizing R&D’s ROI through Better Understanding of Customer          Value  CO-FACILITATORS:  Sheila Mello, Managing Partner and Principal Consultant, Product  Development Consulting, Inc.  Annemari Cooley, Business Development Manager,  Welch Allyn, Inc.  Wayne Mackey, Principal, Product Development Consulting, Inc.  Learn how you can help your company maximize the return on its  research and development budget by understanding what companies in  your market space value. All cross-functional organizations are involved in  the realization of innovative product development. This session will cover  how device companies can determine how/where the effective use of both  qualititative and quantitative customer exploration can optimize bottom  line growth. You will have the opportunity to participate in a very  interactive session to explore the approaches and impediments to  integrating customer value into your product development decision-making  and hear a case study from Annemari Cooley, Manager of Strategic   Alliances and OEM Technologies at Welch Allyn.  Some of the best practices that will be explored include: The appropriate use of qualitative vs. quantitative customer research Understanding what gets in your customer’s way of achieving their objectives Creating a story of what it is like to be a person with problems that your product would solve Translating what the customer / consumer told you into measurable customer requirements that are understood and agreed upon by marketing and new product development Using qualitative research including the Kano Methodology to decide where to invest your R&D dollars Integrating a cross functional team to avoid lengthy discussions and misinterpretations during product development  BP2: Sales & Marketing Collaboration to Drive Revenues  CO-FACILITATORS:  Jerry Alderman, Senior Vice President, Exogen  Chad Fenbert, Director of Sales, Owens Corning  Consumers continue to demand a higher quality, lower cost healthcare  experience. In order to meet this demand and strengthen their value  proposition, Providers, Manufacturers, Payers, Physicians, and all other  members of the Healthcare value system need to align their strategies and  investments around their customers to create customer value.  Effective  sales and marketing collaboration is a vital component in driving this  transformation as it ensures the most valuable needs of customers are  known.   This interactive session will discuss the process of combining  your  sales and marketing expertise with an ‘Outside-In’ customer  perspective to develop a quantified portfolio of profitable growth  opportunities through customer value creation. Hear a case study from  Chad Fenbert, Director of Sales, at Owens Corning on how their  organization’s sales and marketing organizations work together to identify  value creation opportunities for their customers.    Key Take-Aways: Get perspective on where the healthcare industry is today in terms of being customer focused Understand why it is important to align your strategies around opportunities to create value Learn about collaboration methodologies for sales and marketing to strengthen your competitive advantage by creating customer value Discuss methods to change traditional sales conversations about price to discussions about value    BP3: Achieving Business Excellence for Medical Device Companies  CO-FACILITATORS:  David Matheson, President & CEO, SmartOrg, Inc.  Don Cresswell, Vice President, Sales and Marketing, SmartOrg, Inc.  Bill Antwerp, Distinguished Scientist, Corporate Science and Technology,   Medtronic  A survey of thought leaders revealed a wide range of issues that directly  affect Business Excellence including: impact of regulatory environment on  business excellence; understanding trade-offs between evolutionary and  revolutionary technologies; moving quickly; identifying emerging markets  and how to develop and launch new products/platforms in a robust and  rapid manner; how to best move from ideation into and out of R&D, and  how to choose markets outside the U.S. While these are diverse subjects,  there is a common thread: making good decisions under conditions of  uncertainty.     The Distinguished Scientist, Corporate Science and Technology at  Medtronic will bring lessons learned from his extensive experience with  this leading medical device manufacturer. He will be assisted by experts in  R&D and New Product Development decision-making, including the co-  author of the best-selling Harvard Business School Press book “The Smart  Organization: Creating Value through Strategic R&D” and leader of a  seminal benchmark study in R&D decision-making.  Key Take-Aways: Understanding trade-offs between evolutionary and revolutionary technologies Identifying emerging markets and how to develop and launch new products/platforms in a robust and rapid manner How to best move from ideation into and out of R&D
12:00pm	INTERACTIVE  Solutions Wheel  Play the "wheel" and join a series of rapid-fire one-on-one meetings with  leading solution providers.  Runs concurrently with:  Town Hall - Don't miss the opportunity to join your peers for an open mic  forum to discuss the biggest challenges and the hottest topics facing you  every day.
12:45pm	The Power Lunch: Networking Discussions Hosted by Industry  Leaders  Practitioners and solution providers host a menu of luncheon discussions  on pertinent industry issues. Dine and dish with industry experts. The list of  roundtable discussion topics will be available on-site.
1:45pm	INTERACTIVE Breakout Sessions: Create, Communicate & Connect  Participant-driven discussions focusing on your key challenges and  concerns.  Choose one of the following:  RT1: Managing Risk in Early Stage Innovation  FACILITATOR:  Todd Hein, Senior. Director – Medical Devices, Life Science Industry  Business Unit, Oracle  Topics of discussion will include risk management associated with: Capturing & managing design inputs Cross function collaboration practices Quality Assurance framework in the development process Regulatory submission strategy  RT2: Ethnographic Considerations in Device Research  CO-FACILIATORS:  Gerry Katz , Executive Vice President, Applied Marketing Science  John Mitchell, Principal, Applied Marketing Science  This interactive roundtable discussion will make the case for (and against)  using contextual observation to gather the Voice of the Customer in  medical device product development.  Key Take-Aways: The strengths and weaknesses of using ethnography to gather customer needs Examples of successful ethnographic applications Complications that could arise in gaining access, recording interviews, and negotiating privacy/HIPPA issues Alternatives to ethnography you should also consider  RT3: Minimizing the Impact of Product Recalls: Preparing a Regulatory           Strategy  CO-FACILIATORS:  Schuyler Ritter, SVP, Business Development, Beaufort Advisors  Margaret Deul, Vice President, Project Management, Beaufort Advisors  Key Take-Aways: Learn how to use regulatory affairs strategically rather than defensively Define your corrective/preventive action plan up front. Convince your team that recalls happen to every company at some point; being prepared is a competitive advantage Examples of effective regulatory planning and FDA communication that will help in the event of a recall Hear what not to do from peers in the Medical Devices field
3:15pm	Networking, Refreshments and Exhibition Break
3:45pm	CASE HISTORY  The Reimbursement Challenge in Bringing New Technologies to  Market- You Want to Get Paid for That  Jacob Drapkin, Vice President, Reimbursement & Healthcare Economics,  Ethicon Endo-Surgery, Inc, A Johnson & Johnson Company  It is important to proactively plan for reimbursement & healthcare  economics.  This discussion will give you a better understanding of the  market dynamics from a payor's perspective so you can identify the  appropriate value proposition for your technology.  We will explore the  various forces that affect market penetration of medical technology and  gain an understanding of when to begin reimbursement planning, and the  data that will be required.  Key Take-Aways: How pricing ties into reimbursement Explore various reimbursement strategies and review case studies What is the current impact of the health insurer? What impact will health technology assessment have on your technology?
4:30pm	INTERACTIVE  Ask the Experts! Panel Discussion   IP Strategy in an Innovation-Driven Business  MODERATOR:  Jim Stommen, National Editor, Medical Device Daily  Panelists Include:  Tracy Accardi, Vice President, Global Research and Development, Patient   Care and Safety Products, Covidien, Ltd.  Tom Oliver, Vice Chairman, CoolSystems, Inc., Makers of Game  Ready  Ken Olson, Vice President, Research and Development, Medtronic Inc.  Tony Diehl, General Counsel, Insulet Corporation  Eric Chan, Chief Technology Officer, Cardima, Inc.  The experience of panelists in a wide range of intellectual property issues  will be drawn upon in this program, which is focused on development of an  IP strategy appropriate to innovation-driven businesses. The intent of this  interactive session is for the panelists to apply insights gathered in their  dealings with IP issues they have experienced to matters of interest raised  by members of the audience. The importance of IP to a company’s growth  and development, coupled with “how-to” advice on managing patent and  copyright issues, is expected to be a central part of the discussion.    Among the take-away points likely to be discussed in this Ask the  Experts session: How changes in patent law affect their procurement, enforcement and defense IP issues in partnering with academia and government organizations Acquisition of emerging companies’ IP IP issues in China and other emerging international markets
5:15pm	Panel Discussion Concludes
5:30pm	Networking Reception
6:45pm	Meet in Lobby for Wine & Dine Departure

Tuesday, March 11th, 2008 - GENERAL SESSION AND EXHIBITION
8:00am	Continental Breakfast and Exhibition
8:30am	Ice Breaker and Overview  Patrick Nugent, Executive MindXchange Chairperson, Frost & Sullivan
8:45am	MOVER & SHAKER LIVE  Interview with an Industry Trailblazer –Personalized Medicine  Joseph M. DeVivo, Global President, Reconstructive Orthopaedics,  Smith & Nephew, Inc.
9:30am	SUCCESS STORY  Business Model Innovations for Growth   Dr. Marcus Schabacker, M.D.,Ph.D., Senior Vice President and Chief  Scientific Officer, Conva Tec,A Bristol-Myers Squibb Company   In this session, the Chief Scientific Officer of ConvaTec,A Bristol-Myers   Squibb Company, will share key learnings from their recent  implementation of a Product Development and Launch Process, which was  designed to improve the methodology, tracking and management of their  new product pipeline, while optimizing growth and innovation opportunities.  Participants will learn about the overall model that was implemented, along  with Idea Management process, the project and portfolio management and  metrics measurements that were developed to allow for continuous  improvement opportunities of the new process. Additionally, key insights  and examples of the process development activities, governance  formation, communications and global implementation will be shared. The  results of this implementation have translated into improved project  oversight, better decision making for new product development entry  opportunities and active portfolio management as well as a significant  increase in pipeline value. Furthermore ConvaTec included financial  metrics and key performance indicators in their five year strategic plan,  which are closely tied to the new innovation process and will help to steer  and direct the new product development portfolio.  Key Take-Aways: Top five actions that must take place to insure the successful implementation and transition to a new Product Development Process Building opportunities for growth and innovation within the new business model Insights into the governance development, change management process, and communications tools utilized to implement a global process change
10:15am	Networking, Refreshment and Exhibition Break
10:45am	INTERACTIVE  VITAL VIEWPOINTS – Strategic Go-to-Market Considerations  MODERATOR:  Les Sprinkle, Senior Vice President, Orthopaedic Reconstruction, Smith &  Nephew, Inc.  SOLUTION PROVIDER PANELISTS INCLUDE:  Sean  Macleod, President, Stratos Product Development  Wade Lukianow, Design Center Vice President, Plexus Corporation  Manoj Kenkare, Senior Director, Life Sciences, HCL Technologies Ideation and Concept Convergence Time-To-Value Creation With an offshore R&D partner
11:45am	GROWTH INSIGHTS  Profitable Innovation: Integrating Market Pull and Technology  Push  Peter A. Burke, Ph.D., Senior Vice President and Chief Technology Officer,  STERIS Corporation  The interface between Marketing and R&D is critical for rapid product  development that provides enhanced values through unique selling  features to valued customers.  Creative new products can and should be  driven both from a Marketing and R&D development perspective  depending on the direction of the development.  The major points of  emphasis are: How to drive market share through voice of the customers’ studies How to disrupt a marketplace through new technology interaction How to manage the tension created through vibrant Marketing / R&D exchanges
12:30pm	INTERACTIVE  Solution Wheel: Play the "wheel" and join a series of rapid-fire, one-on-  one meetings with leading solution providers.
1:00pm	Food For Thought - Networking Luncheon Featuring Thought  Leader Hosted Discussions  Thought Leaders host a menu of luncheon discussions on pertinent  industry issues. Dine and dish with industry experts. The list of discussion  topics will be available on-site.
2:00pm	INTERACTIVE Breakout Sessions: Create, Communicate & Connect  Participant-driven discussions focusing on your key challenges and  concerns.  Choose one of the following:     TT1: Opportunity Discovery “Boot Camp”: Leveraging the Care Pathway  CO-FACILITATORS:  Simon Karger, Director, Innovation & Technology Management, USA,  Sagentia Inc  Dan Edwards, Director, Innovation & Technology Management, USA,  Sagentia Inc  This interactive session will draw on and enable a sharing of participants’  and the facilitators’ experience of innovation in healthcare. Through a  guided (case study) review of innovations in our industry we will attempt  to uncover both reusable tools and a framework which we can bring back  to the office to illuminate our constant search for new opportunity. This  session will lead to discussion of topics such as … technology disruption,  brand, IP, unmet needs and so on.    Key Take-Aways: A simple framework which describes hunting grounds for opportunity Tools for actually identifying opportunity Case studies in disruptive innovation in healthcare  TT2: Building Sustainable Market Advantage through Value Proposition and           Competitive Assessment  FACILITATOR:  Erik W. Glitman, Managing Director, Fletcher/CSI, LLC  This interactive session will draw on participants’ experiences to illustrate  the ways in which medical device companies can use targeted customer  and competitor research to align the product or service value proposition  with the buyer’s requirements. The discussion will attempt to produce  recommendations for best practices in value proposition alignment,  creating a template that participants can use on their own products and  service. Highlighting the role of win/loss and competitor intelligence in the  value proposition alignment process, the session will provide real world  examples of successful re-alignment and the outcomes of that alignment.   Participants will have access to the accumulated knowledge of all  participants and the facilitator.  Key Take-Aways: Illustrate the pitfalls that can occur in a CI projects How to apply lessons learned to produce positive, actionable outcomes Factors that contribute to keeping a project on track Provide insight on how to recognize when a project is in Demonstrate the tools that can be used to track project success  TT3: Doing Business in China  CO-FACILITATORS:    Andy Rawlins, Partner and Leader, Medical Device Practice, Foley &   Lardner, LLP  Zhu Lee, Partner, China Team, Foley & Lardner LLP  China and other Asian markets present areas for explosive business  development, and interest and opportunities in those markets have  increased dramatically over the last few years. For U.S. medical device  companies, the opportunities in China are unprecedented but require  careful consideration of business structure and the protection of  technology and intellectual property (IP) assets.  During this session, you will have the opportunity to engage in an informal  roundtable discussion with top legal experts on China and China-US  collaboration. Through hand-on, practical discussion based on real-life  examples, you will learn: Different methods & legal framework a non-Chinese medical device company can employ to expand to China, and pros/cons for each option Top 10 IP and business due diligence issues for cross-border transactions "Do's and don’ts" on International technology transfer, licensing, and portfolio management
3:30pm	Networking, Refreshment and Exhibition Break
4:00pm	EXECUTIVE BULLETIN    Maik Klasen, Ph.D., Director, Healthcare and Life Science Consulting  Group, Frost and Sullivan  Opportunities and Challenges in the Shifting Sites of Care  In 2006, Andy Grove et al. introduced their solution to the problem of an  aging population and its implications on the US healthcare system and its  providers. He called his initiative “shift to the left” and started to discuss  technology that might make preventive care a reality and home care  effective and affordable to the US healthcare system. The “shift to the left”  moves patients out of today’s costly acute care into tomorrow’s home  care. We ask: Who is on a move – an industry or patient care?    Key Take-Aways: Participants will gain insights into a new developing market The session will guide participants through this developing market space and will make you aware of the basic market forces
4:45pm	EXECUTIVE INSIGHTS    Unlocking China’s Market Potential  Glenn Xuchao Hou, Consulting Manager, Healthcare Practice, Frost &  Sullivan China  In this session, the country consulting manager of Frost & Sullivan China  Healthcare Practice, will introduce the dynamic of the fast moving Chinese  medical device market. Historical successful growth strategies, current  market environments, and future opportunities are to be identified through  an interactive discussion. Several case studies of successful market  strategies cover wholly foreign funded, Sino-foreign Joint Venture and  Domestic Enterprise. Current market overview, competitive landscape and  government regulatory issues will be provided. Moreover, identified  market trends and opportunities in the next 3-5 years will be discussed. A  list of key factors to be considered when measuring/identifying an  opportunity and its potential will be generated. Participants will have a  broad idea of China’s medical device market, and be able to identify the  market potential with an information based opportunity evaluation tool kit.    Key Take-Aways: Several case studies of successful medical device companies in China Key trends and market potential in the next 3-5 years backed up by data Top ten issues/factors to be considered when identifying the market opportunity
5:30pm	Executive MindXchange Concludes
6:00pm	Blowout Reception  Escape to Alcatraz!   A Can’t Miss Medical Devices and Venture Connections tradition with open  bar, prison break buffet and live entertainment!  Access is complimentary  for all event participants, confirm your attendance during registration.

Wednesday, March 12th, 2008 VENTURE CONNECTIONS 2008 : A CO-LOCATED EVENT BRINGING TOGETHER MEDICAL DEVICES, LIFE SCIENCES AND VENTURE CAPITAL EXECUTIVES TO SHOWCASE AND EVALUATE THE MOST PROMISING, SOLID INVESTMENT OPPORTUNITIES IN TODAY'S MARKET.
8:00am	Exclusive Investor Networking Breakfast  Hosted by Frost & Sullivan's Financial Services and Healthcare Industry  Practices.  Informal discussion on markets, technologies, deal flow and  due diligence best practices, success stories on niche medical device  investments, and more.
8:15am	Registration and Participant Continental Breakfast For all participants and presenting companies
8:45am	Ice Breaker, Welcome and Introduction Patrick Nugent, Executive Symposium Chairperson, Frost & Sullivan
9:00am	MOVER AND SHAKER LIVE! Interview with an Industry Luminary Mike Smith, Founding Principal, Gulf Capital Partners Mr. Smith is a founding principal of Gulf Capital Partners, Inc. His professional background includes many years of operating and engineering experience which provides a strong commercial perspective combined with his extensive experience in corporate finance and mergers and acquisitions on Wall Street. MODERATOR: Edward Endicott, Business Development Manager, Financial Services Group, Frost & Sullivan
9:45am	CONCURRENT TRACKS TRACK I: CALLS FOR CAPITAL: Company Business Plan Presentations 9:45am - Jeff Williams, President and Chief Executive Officer, HandyLab Inc 9:55am - Richard Testa, President, AlphaMed Inc. 10:05am - Reinhard Warnking, Chief Executive Officer, Pro Rhythm, Inc. 10:15am - Philip Manly, President, Connect Imaging Inc. 10:25am - David Denise, Senior Director-IT, Stinger Medica TRACK II: INTERACTIVE SESSION: Insight, Opti-price® and Due Diligence as Essential Steps in Early Stage Product Valuation CO-FACILITATORS: Christopher Jones, D.Phil., Director, Health Economics and Outcomes Research, The Aequitas Group, Inc.       Charmie Chirgwin, R.N., Managing Director, Business Development, The Aequitas Group, Inc. In the last 5 years, we have seen rapid growth in two key areas: early stage product valuation and due diligence.  Early stage product valuation can be a moving target. Components such as inflation, currency differentials, price hikes, regulatory changes, fluctuating market capture, and unknown impact of future competitors do little to place this target in clear sight. Determining where the target will be in the near-, middle- and long-term is of paramount importance, particularly for product commercialization and payer uptake.  Oftentimes, the structure of a clinical trial can affect the potential reimbursement of a product or therapy by today’s private and public payers. Whereas due diligence has traditionally been used as a verifying tool – a box to tick – such a narrow approach can be a costly mistake if valuable information is overlooked. Participants will be asked to share their experiences including lessons learned from “nightmare stories”, and how they have used due diligence as a “deal breaking” tool. In addition, participants will be asked when and in what context one might consider using investigative due diligence as a “deal making” tool. A meaningful combination of insight with due diligence can create a product that is more valuable than the sum of the parts. By the end of this session, participants will receive insights on how to: Choose the right strategy consulting partner who offers insight rather than hindsight Utilize Opti-price® to evaluate early-stage IP based on changing market assumptions; where inventors, company executives, angel financiers, and second-stage funding bodies will be offered an interdisciplinary approach to evaluating and establishing long-term product value Engage the right partner to investigate market competition, perform multiple levels of due diligence and test or establish a value proposition
10:30am	Networking and Refreshment Break
11:00am	INTERACTIVE Ask the Experts! Panel Discussion: The VC Buzz MODERATOR: Ken Herbert, Vice President, Global Business and Financial Services, Frost & Sullivan PANELISTS INCLUDE: Jonathan Norris, Managing Director, Private Equity Group, SVB Capital Roger Flugel, Ph.D., Principal, Sanderling Ventures Ramsey Battin, Director, Arcapita Ventures John Lonergan, Managing General Partner, Mach Ventures, LP
11:45am	CONCURRENT TRACKS TRACK I: CALLS FOR CAPITAL: Company Business Plan Presentations 11:45am - Robert Koenigsberg, President/CEO/Founder, SleepQuest, Inc. 11:55am - Robert Webber, Ph.D., President and CEO, R&D Antibodies 12:05pm - Craig Misrach, President, Freedom Meditech 12:15pm - Vinit Saxena, President & CEO, Sepragen Corporation TRACK II: INTERACTIVE SESSION: Smart Reimbursement Planning FACILITATOR: Ronald Podraza, J.D., Chief Executive Officer, Reimbursement Principles, Inc. The new higher hurdles for reimbursement coding and coverage require early planning in the product development process.  Participants and facilitators will discuss: Principles of coding strategy How to generate evidence supporting reimbursement during FDA clinical trials How to support a product launch in a tough reimbursement environment Attend this interactive session and contribute to this lively discussion on this make-or-break topic
12:30pm	Networking Luncheon
1:30pm	CONCURRENT TRACKS TRACK I: CALLS FOR CAPITAL: Company Business Plan Presentations 1:30pm - Bart J. Doedens, President & CEO, Atlas Spine Inc. 1:40pm - Handel You, Chief Financial Officer, Vivax Medical 1:50pm - Eugene Bajorinas, Vice President Operations, Novian Health Inc. 2:00pm - Nadim Assi, President, Softmedical TRACK II: INTERACTIVE SESSION: IP Strategy in an Innovation-Driven Industry CO-FACILITATORS: Gary Liberson, Vice President of Marketing, PA Consulting Jaime J. Lewis, Principal, Paperboy Ventures, LLC This informal, interactive roundtable discussion will focus on topical matters of interest, facilitated by industry experts.  The objective of this session is to foster networking among the group, capture the primary issues to discuss, promote the cross-sharing of knowledge and achieve consensus or closure on key issues. Thought Leaders will take an active role in these sessions to help promote interaction and bring a balanced perspective to the discussion.
2:15pm	INTERACTIVE Ask the Experts! Panel Discussion: The Buzz from Institutional and Corporate Venture Arm Investors MODERATOR: Emily Westhafer, Events Editor, Financial Information Services, Dow Jones & Co.  PANELISTS INCLUDE: William Hoos, Business Manager, Sleepwell Ventures, Respironics, Inc. Nick Kim, Managing Director, Corporate Finance, Institutional Securities Group, N. Hahn & Co., Inc. Adeo Ressi, Founding Member, The Funded Companies seeking funding, incubation and buyout need to know the buzz – what trends are taking place in the medical devices, lifesciences, bio-tech and healthcare industries as a whole.  This panel will share their knowledge on these and all of the other burning questions that will help start-up and growth companies determine their approach and strategy for the future so bring your questions as these investors prepare to discuss: What changes if any in patent law will / are advantaging or disadvantaging medical device/technology healthcare/bio startup companies? From the first meeting, describe your process for closing a deal (in terms of activities, timing, etc). Are deals pricing up?  What is the value of a deal?  What trends is your company seeing on the horizon – who is investing in what – why?
3:00pm	Networking and Refreshment Break
3:30pm	CONCURRENT TRACKS TRACK I: CALLS FOR CAPITAL: Company Business Plan Presentations 3:30pm - Patrick Humm, Chairman and CEO, Hie Electronics, Inc. 3:40pm - Beverly Dunlap, Director, Business Development, Histogen, Inc 3:50pm - John G. Voeller, Chief Technology Officer, HealthCard, Division of General Integration 4:00pm - Michael Wilkinson, Chief Executive Officer, Kewl Innovations, LLC TRACK II: INTERACTIVE SESSION: Exit Strategy Brainstorm FACILITATOR: Steve Bengston, Managing Director Emerging Company Services, PricewaterhouseCoopers PANELISTS INCLUDE: John Lonergan, Managing General Partner, Mach Ventures John Steuart, Managing Director, Claremont Creek Ventures Mark Brooks, Managing Director, Scale Ventures Fred Aslan, M.D., Vice President, Venrock Associates Exits have tilted more towards M&A than ever in the past 5 years with the luke warm IPO market.  Is this a permanent change or just another cycle?  When, if ever, will we see a robust IPO market for life science companies again?  Come hear a panel of experts opine on how to maximize your exit and answer your questions.
4:15pm	KEYNOTE An IPO Success Story Joseph V. Gulfo, MD, MBA, President and CEO, Electro Optical Sciences   Learn how Electro-Optical Sciences, Inc., an innovator in the field of medical computer vision technology, recently closed a $9 million extension of its Series C Preferred financing. In addition, the company has secured a Protocol Agreement with the US Food & Drug Administration (FDA) for its Pre-market Approval (PMA) Application pivotal clinical trial of MelaFind®, EOS’ proprietary diagnostic system for the early detection of melanoma. EOS is a medical device company focused on designing and developing a  non-invasive, point-of-care instrument to assist in the early diagnosis of  melanoma. MelaFind(R), EOS's flagship product, features a hand-held  imagingdevice that emits light of multiple wavelengths to capture images of  suspicious pigmented skin lesions and extract data. Using sophisticatedalgorithms, the data are then analyzed against a proprietary database of melanomas and benign lesions in order to provide information to the physician and produce a recommendation of whether the lesion should be biopsied.
5:00pm	Networking Reception